[{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"||GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for SAGE-217

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Zurzuvae (zuranolone), the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD.

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 14, 2023

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Sage Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum dep...

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 31, 2023

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Biogen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 03, 2023

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Sage Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 02, 2023

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Biogen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum dep...

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 08, 2023

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Sage Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported.

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 17, 2022

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Sage Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2022

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Biogen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : SAGE-217 (zuranolone) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric m...

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 12, 2022

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Sage Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : At the Day 3 primary endpoint, SAGE-217/BIIB125 (Zuranolone), investigational oral neuroactive steroid GABA-A receptor-positive allosteric modulator, 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction i...

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 16, 2022

                          Lead Product(s) : Zuranolone,Escitalopram Oxalate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Biogen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : SAGE-217/BIIB125 (zuranolone) is a once-daily, two-week, investigational drug in development for treatment of major depressive disorder and postpartum depression. Zuranolone is an investigational oral neuroactive steroid (NAS) GABA-A receptor positive al...

                          Product Name : SAGE-217

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 05, 2022

                          Lead Product(s) : Zuranolone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Biogen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank